Inventor · disambiguated record
Argeris N. Karabelas
Also filed as: KARABELAS ARGERIS · KARABELAS ARGERIS N
1 granted patent·10 pending applications·11 citations·filing 2011–2025
36Inventor score
Top patents by PatentIndex Score
11 records- 0177US9732059B2Methods of use of cyclic amide derivatives to treat schizophreniaLUTHRINGER REMY HENRI·Filed 2011·Granted Aug 15, 2017·11 cites·25 claims
- 0273US2025109127A1Methods of use of phenoxypropylamine compounds to treat depressionMINERVA NEUROSCIENCES INC·Filed 2024·Application pending·0 cites
- 0372US2025179044A1Methods of use of cyclic amide derivatives to treat schizophreniaMINERVA NEUROSCIENCES INC·Filed 2024·Application pending·0 cites
- 0465US2022274951A1Methods of use of cyclic amide derivatives to treat schizophreniaMINERVA NEUROSCIENCES INC·Filed 2022·Application pending·0 cites
- 0563US2025228838A1Methods of use of cyclic amide derivatives to treat sigma receptor mediated disordersMINERVA NEUROSCIENCES INC·Filed 2025·Application pending·0 cites
- 0661US2021106573A1Methods of use of cyclic amide derivatives to treat sigma receptor mediated disordersMINERVA NEUROSCIENCES INC·Filed 2020·Application pending·0 cites
- 0754US2020223838A1Methods of use of phenoxypropylamine compounds to treat depressionMINERVA NEUROSCIENCES INC·Filed 2020·Application pending·0 cites
- 0851US2018155318A1Methods of use of cyclic amide derivatives to treat schizophreniaMINERVA NEUROSCIENCES INC·Filed 2017·Application pending·0 cites
- 0949US2014206722A1Methods of use of phenoxypropylamine compounds to treat depressionMINERVA NEUROSCIENCES INC·Filed 2014·Application pending·0 cites
- 1046US2016354357A1Methods of use of cyclic amide derivatives to treat sigma receptor mediated disordersMINERVA NEUROSCIENCES INC·Filed 2016·Application pending·0 cites
- 1143US2013274290A1Methods of use of cyclic amide derivatives to treat sigma receptor mediated disordersLUTHRINGER REMY HENRI·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Argeris N. Karabelas files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →